Skip to main content
SpringerLink
Log in

Evaluation of IGF-I levels during long-term somatostatin analogs treatment in patients with gastroenteropancreatic endocrine tumors

  • Original Articles
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Previous experiments reported desensitization to SS action in rat anterior pituitary cells and cell lines. The aim of the study was to verify whether the lack of desensitization to SS analogs (SSa) observed in acromegalic patients was also present in subjects with normal hypothalamic-pituitary function. The effect of chronic treatment with octreotide long-acting release (o-LAR, 10–30 mg/28 days) on IGF-I levels was then evaluated in 23 patients with gastroenteropancreatic (GEP) endocrine tumors (8 gastrinomas, 6 carcinoids, and 9 functioning pancreatic tumors). Serum IGF-I, clinical symptoms, plasma chromogranin-A (CgA) and markers of hepatic synthesis were evaluated before and after a short-term period in all the patients (median 4.5 months), after a medium-term period in 12 (median 18 months) and after a long-term follow-up period in 9 of them (median 48 months). Mean IGF-I levels decreased from 17.3±7.0 to 12.8±6.2 nmol/l in the short-term (p<0.005) being reduced from baseline concentrations in 87% and under the normal range for age in 35% of patients. Afterwards, they always remained stable both in the medium- and long-term periods, still being low in 3/12 and 2/9 patients, respectively. No alterations in biochemical markers of liver function were found either before or during therapy. No correlation between IGF-I levels, CgA concentrations and/ or clinical definitive outcome was observed. In conclusion, the study demonstrated that: a) similarly to that observed in acromegalic patients, chronic o-LAR treatment did not induce desensitization of pituitary SS receptors (SSR) in humans with intact hypothalamic-pituitary axis, and b) in patients with GEP endocrine tumors, GH/IGF-I inhibition did not contribute to SSa efficacy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Reichlin S. Somatostatin. N Engl J Med 1983, 309: 1495–501.

    Article  PubMed  CAS  Google Scholar 

  2. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB. The somatostatin receptor family. Life Sci 1995, 57: 1249–65.

    Article  PubMed  CAS  Google Scholar 

  3. Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr Rev 1995, 16: 427–42.

    PubMed  CAS  Google Scholar 

  4. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med Mol Imaging 2001, 28: 836–46.

    Article  CAS  Google Scholar 

  5. Fjällskog ML, Ludvigsen E, Stridsberg M, Öberg K, Eriksson B, Janson ET. Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. Med Oncol 2003, 20: 59–68.

    Article  PubMed  Google Scholar 

  6. Hofland LJ, Lamberts SWJ. The pathophysiological consequences of somatostatin receptor internalisation and resistance. Endocr Rev 2003, 24: 28–47.

    Article  PubMed  CAS  Google Scholar 

  7. Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991, 12: 450–82.

    Article  PubMed  CAS  Google Scholar 

  8. Lamberts SWJ. Octreotide. N Engl J Med 1996, 334: 246–54.

    Article  PubMed  CAS  Google Scholar 

  9. Davies PH, Stewart SE, Lancranjan L, Sheppard MC, Stewart PM. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol (Oxf) 1998, 48: 311–6

    Article  CAS  Google Scholar 

  10. Caron P, Morange-Ramos I, Cogne M, Jaquet P. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 1997, 82: 18–22.

    PubMed  CAS  Google Scholar 

  11. Garland J, Buscombe JR, Bouvier C, et al. Sandostatin LAR for malignant carcinoid syndrome: a 3-year experience. Aliment Pharmacol Ther 2003, 17: 437–44.

    Article  PubMed  CAS  Google Scholar 

  12. Öberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004, 15: 966–73.

    Article  PubMed  Google Scholar 

  13. Viola KV, Sosa JA. Current advances in the diagnosis and treatment of pancreatic endocrine tumors. Curr Opin Oncol 2005, 17: 24–7.

    Article  PubMed  CAS  Google Scholar 

  14. Hofland LJ, van Koetsveld PM, Waaijers M, Zuyderwijk J, Breeman WA, Lamberts SW. Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide. Endocrinology 1995, 136: 3698–706.

    PubMed  CAS  Google Scholar 

  15. Hofland LJ, Breeman WA, Krenning EP, et al. Internalization of [DOTA°,125I-Tyr3]Octreotide by somatostatin receptor-positive cells in vitro and in vivo: implications for somatostatin receptor-targeted radio-guided surgery. Proc Assoc Am Physicians 1999, 111: 63–9.

    Article  PubMed  CAS  Google Scholar 

  16. Di Bartolomeo M, Bajetta E, Buzzoni R, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 1996, 77: 402–8.

    Article  PubMed  Google Scholar 

  17. Consensus statement: benefits versus risks of medical therapy for acromegaly. Acromegaly Therapy Consensus Development Panel. Am J Med 1994, 97: 468–73.

    Article  Google Scholar 

  18. Cozzi R, Attanasio R, Montini M, et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 2003, 88: 3090–8.

    Article  PubMed  CAS  Google Scholar 

  19. Del Pozo E, Neufeld M, Schluter K, et al. Endocrine profile of a long-acting somatostatin derivative SMS 201–995. Study in normal volunteers following subcutaneus administration. Acta Endocrinol (Copenh) 1986, 111: 433–9.

    Google Scholar 

  20. Wurzburger MI, Prelevic GM, Sonksen PH, Balint-Peric LA. The effect of the somatostatin analogue octreotide on growth hormone secretion in insulin-dependent diabetics without residual insulin secretion. Horm Metab Res 1992, 24: 329–32.

    Article  PubMed  CAS  Google Scholar 

  21. Pollak MN, Polychronakos C, Guyda H. Somatostatin analogue SMS 201–995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. Anticancer Res 1989, 9: 889–91.

    PubMed  CAS  Google Scholar 

  22. Cascinu S, Del Ferro E, Grianti C, et al. Inhibition of tumor cell kinetics and serum insulin growth factor I levels by octreotide in colorectal cancer patients. Gastroenterology 1997, 113: 767–72.

    Article  PubMed  CAS  Google Scholar 

  23. Macaulay VM, Smith IE, Everard MJ, Teale JD, Reubi JC, Millar JL. Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer. Br J Cancer 1991, 64: 451–6.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  24. O’Byrne KJ, Dobbs N, Mitchell K, Woodhul l, Harris AL. Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer. Br J Cancer 1999, 79: 1413–8.

    Article  PubMed Central  PubMed  Google Scholar 

  25. Figg WD, Thibault A, Cooper MR, et al. A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer. Cancer 1995, 75: 2159–64.

    Article  PubMed  CAS  Google Scholar 

  26. Spada A, Elahi FR, Arosio M, et al. Lack of desensitization of adenomatous somatotrophs to growth-hormone releasing hormone in acromegaly. J Clin Endocrinol Metab 1987, 64: 585–91.

    Article  PubMed  CAS  Google Scholar 

  27. Wymenga AN, Eriksson B, Salmela PI, et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 1999, 17: 1111.

    PubMed  CAS  Google Scholar 

  28. Epaminonda P, Porretti S, Cappiello V, Faglia G, Arosio M. Efficacy of radiotherapy in normalizing serum IGF-I, acid-labil subunit (ALS) and IGF-BP3 levels in acromegaly. Clin Endocrinol (Oxf) 2001, 55: 183–9.

    Article  CAS  Google Scholar 

  29. Peracchi M, Conte D, Gebbia C, et al. Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1. Eur J Endocrinol 2003, 148: 39–43.

    Article  PubMed  CAS  Google Scholar 

  30. Smith MA, Yamamoto G, Vale WW. Somatostatin desensitization in rat anterior pituitary cells. Mol Cell Endocrinol 1984, 37: 311–8.

    Article  PubMed  CAS  Google Scholar 

  31. Presky DH, Schonbrunn A. Somatostatin pretreatment increases the number of somatostatin receptors in GH4C1 pituitary cells and does not reduce cellular responsiveness to somatostatin. J Biol Chem 1998, 263: 714–21.

    Google Scholar 

  32. Tulipano G, Stumm R, Pfeiffer M, Kreienkamp HJ, Hollt V, Schulz S. Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes. J Biol Chem 2004, 279: 21374–82.

    Article  PubMed  CAS  Google Scholar 

  33. Thobois S, Vingerhoets F, Fraix V, et al. Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study. Arch Neurol 2004, 61: 1705–9.

    Article  PubMed  Google Scholar 

  34. Mannavola D, Persani L, Vannucchi G, et al. Different responses to chronic somatostatin analogues in patients with central hyperthyroidism. Clin Endocrinol 2005, 62: 176–81.

    Article  CAS  Google Scholar 

  35. Chen JW, Hojlund K, Beck-Nielsen H, et al. Free ratherthan total circulating insulin-like growth factor-I determines the feedback on growth hormone release in normal subjects. J Clin Endocrinol Metab 2005, 90: 366–71.

    Article  PubMed  CAS  Google Scholar 

  36. Murray RD, Kim K, Ren SG, Chelly M, Umehara Y, Melmed S. Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest 2004, 114: 349–56.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  37. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000, 21: 215–44.

    Article  PubMed  CAS  Google Scholar 

  38. Shojamanesh H, Gibril F, Louie A, et al. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 2002, 94: 331–4.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unit of Endocrinology, Department of Medical Sciences, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, University of Milan, Via F. Sforza 35, 20122, Milano, Italy

    C. L. Ronchi MD, S. Corbetta, P. Beck-Peccoz & A. Spada

  2. Unit of Gastroenterology, Department of Medical Sciences, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy

    M. Peracchi, S. Massironi, C. Ciafardini & D. Conte

Authors
  1. C. L. Ronchi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Peracchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Corbetta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Massironi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Ciafardini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D. Conte
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P. Beck-Peccoz
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Spada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. L. Ronchi MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ronchi, C.L., Peracchi, M., Corbetta, S. et al. Evaluation of IGF-I levels during long-term somatostatin analogs treatment in patients with gastroenteropancreatic endocrine tumors. J Endocrinol Invest 30, 241–246 (2007). https://doi.org/10.1007/BF03347432

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03347432

Key Words

Search

Navigation